What does real-world evidence tell us about therapies targeting the CGRP pathway in migraine prevention?

Four monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway are currently approved by the US Food and Drug Administration and European Medicines Agency for the preventive therapy of migraine.^1–3 These agents target either the CGRP ligand or its receptor and each has demonstrated efficacy and safety in short- and long-term clinical trials.